Article Text

Download PDFPDF

Meningococcal disease due to W135: fresh public health concerns
  1. P BOLT,
  2. J BRITTO,
  3. S NADEL,
  4. M LEVIN
  1. Department of Paediatrics
  2. Imperial College School of Medicine at
  3. St Mary's Hospital
  4. South Wharf Rd
  5. London W2 1NY, UK
  6. email: j.britto{at}

    Statistics from

    Editor,—The paediatric intensive care unit at St Mary's Hospital in London admits more than 100 cases of meningococcal disease each year from over 50 different hospitals in the south east of England. Since 1992, the unit has treated over 650 patients with the disease,1 but had not treated a single case of serogroup W135 meningococcal infection until April 2000. We would like to report four children treated at our hospital for meningococcal infection due to serogroup W135, type 2A, subtype P1.2, P1.5, within a one month period from April 2000. They had been vaccinated recently with meningococcal serogroup C conjugated vaccine, and had all been in contact with travellers returning from Mecca. The clinical features of these cases are outlined in table 1.

    Table 1

    Clinical presentation, severity and outcome

    The children represent four out of 38 cases (with five fatalities) of serogroup W135 Neisseria meningitidisinfection in England and Wales within the six week period from March to May 2000 (PHLS Meningococcal Reference Unit, personal communication), with hundreds of cases of the identical subtype being reported throughout Europe.2 3 Saudi Arabia has reported over 225 cases, with almost 25% mortality to the end of April 2000.3 It is thought that this large outbreak of an unusual strain originated in Saudi Arabia, with the pilgrimage of a record 1.3 million people to the Haj between 15–18 March 2000.3 4

    A similar outbreak occurred in 1987, due to serogroup A, subgroup III. This also followed the yearly pilgrimage to Mecca, and spread throughout Europe, USA, and Africa over the next two years.5 Requirements for pilgrims entering Saudi Arabia now include documented vaccination with meningococcal A and C polysaccharide preparation. This public health measure has been effective in irradicating serogroup A disease in these travellers.4 A quadravalent vaccine is available for serogroup W135 as well as serogroups A, C, and Y. This vaccine, however, is not licenced in the UK, and is only available on a named patient basis. This raises public health issues, including whether people returning from Mecca to the UK should be screened or given prophylaxis.

    Even with the anticipated beneficial effects of the meningococcal C vaccination programme in England and Wales, it is important to remember that other serogroups of meningococci will continue to cause significant disease in the UK.

    Until 1950, England was predominantly affected by epidemics of serogroup A meningococcal disease. The switch to serogroup B and C disease occurred after the second world war, and serogroup A disease is now rarely seen in the UK. Neisseria meningitidis has the potential to alter its capsular polysaccharide antigen through recombinational exchanges at the capsular locus. In his commentary in theLancet in 1999, Martin Maiden expressed concern that new hypervirulent strains of serogroups including B, W135, and Y may emerge as serogroup C disease is eliminated.6This recent outbreak of serogroup W135 infection does not seem to represent such selection pressure. However, it highlights the need for continued clinical, laboratory, and epidemiological vigilance for meningococcal infection, particularly now that there may be a theoretical risk of other serogroups becoming more prevalent as meningococcal serogroup C disease is controlled.


    View Abstract

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.